The Phase Ia trial is designed to assess the safety and efficacy of the company’s drug designed to target chemicals thought to be a cause of Alzheimer’s disease.

Gum disease appears to disrupt brain activity, potentially increasing a person's risk of cognitive decline. People with gum ...

These sleep aflictions are now recognised in most cases of early dementia – this new discovery could lead to earlier detection ...

A physician would insert a needle into the senator's arm at the clinic, and then, for about two hours a solution would drip ...

Unlike a high-end gym or traditional social clubs that entice people with rare spirits, social wellness clubs are designed as ...